Bahamas vs Luxembourg: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Bahamas
- Luxembourg
How they compare
Bahamas currently reports 60.36 deaths against 57.27 deaths in Luxembourg, a difference of 3.09 deaths.
That makes Bahamas's figure about 1.1 times Luxembourg's.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Luxembourg ahead.
Bahamas ranks 133rd and Luxembourg ranks 134th of 157 countries.
Across the 4 decades both report, Bahamas averaged higher in 3 and Luxembourg in 1.
Head to head by decade
| Decade | Bahamas | Luxembourg | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 8.33 deaths | 8.33 deaths | Luxembourg |
| 2000s | 113.16 deaths | 22.87 deaths | 90.29 deaths | Bahamas |
| 2010s | 136.56 deaths | 37.17 deaths | 99.4 deaths | Bahamas |
| 2020s | 90.13 deaths | 49.91 deaths | 40.22 deaths | Bahamas |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Bahamas or Luxembourg?
- Bahamas, at 60.36 deaths against 57.27 deaths in Luxembourg as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Bahamas and Luxembourg?
- 3.09 deaths, with Bahamas ahead.
- How many years of comparable data are there for Bahamas and Luxembourg?
- 35 years are reported by both, from 1990 to 2024.
- How do Bahamas and Luxembourg rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Bahamas ranks 133rd and Luxembourg ranks 134th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.